enGene Therapeutics Inc. Reports Q3 2026 Financial Results

What Happened

• enGene Therapeutics, Inc. announced its financial results for the three and nine months ended July 31, 2026 in an 8-K filed September 8, 2026 (Item 2.02). The company furnished a press release with the results as Exhibit 99.1 to the Form 8-K.

Key Details

• Date of announcement: September 8, 2026.
• Reporting period: three and nine months ended July 31, 2026.
• Press release is furnished as Exhibit 99.1 to the Current Report on Form 8-K.
• The filing states the furnished information (including Exhibit 99.1) is not being “filed” under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically referenced.
• Form 8-K was signed by CEO Ronald H. W. Cooper.

Why It Matters

• This 8-K provides enGene’s latest quarterly results and is the company’s official update to investors on recent financial performance. Retail investors should review the furnished press release (Exhibit 99.1) for the detailed figures (revenue, net income/loss, cash position, and any operational or clinical updates) that will affect valuation and near-term outlook. The Section 18 disclosure note means the press release is furnished for disclosure but is not subject to certain liabilities that apply to filed reports.